Coti Stories

Aren Shust is one of "the Eight" in a new and up-coming anime called C.O.T.I. (Creatures of the Imagination). This short story gives a glimpse into Aren's life, and reveals how he obtained the plasma. Get ready for a wild ride of humor and a dash of mystery. For more information on C.O.T.I., feel free to find us on Facebook at https://www.facebook.com/creaturesoftheimagination or look us up on our website at creaturesoftheimagination.net. Hope you enjoy! Note: I, along with my co-creator, own the complete rights to the character Aren Shust along with all other content under the C.O.T.I. (Creatures of the Imagination) label. Copyright 2014 Brandon Glattfelder, Skylar Johnson

Welcome to the world of C.O.T.I., or Creatures of the Imagination. This story begins as ordinary as ever, but quickly spirals into action involving mad scientists, mutated superhumans, and worlds outside our own. Join our main heroes on their life-changing adventures. We intend for this story to eventually get created into an anime. For now, we have the ability to share the story through text. We hope you enjoy the fruit of our imaginations. Also, know that because this is a show in the making, there may be slight changes along the way. If anything gets changed throughout the story, we will let you know. Note: I, along with my co-creator, own the complete rights to the characters and storyline under the C.O.T.I. (Creatures of the Imagination) label. Copyright 2014 Brandon Glattfelder, Skylar Johnson For more information on C.O.T.I., feel free to find us on Facebook at https://www.facebook.com/creaturesoftheimagination or look us up on our website at creaturesoftheimagination.net.

https://www.glpbio.com/coti-2.html COTI-2 activates mutant forms of p53. p53 has varoius mechanisms of anticancer function and plays a critical role in genomic stability, apoptosis and inhibition of angiogenesis. In vitro: Previous study tested the efficacy of COTI 2 against a diverse group of human cancer cell lines with different genetic mutation backgrounds. Results showed that COTI-2 efficiently inhibited the proliferation rate of all the tested cell lines following 72 h of treatment. Most cell lines showed nanomolar sensitivity to COTI-2 treatment. In addition, COTI-2 was significantly more effective at inhibiting tumor cell proliferation than either cetuximab or erlotinib in COLO-205, HCT-15, and SW620 cell lines. Notably, all three lines were insensitive to growth inhibition to any degree in response to low concentrations of cetuximab and erlotinib, but highly sensitive to even low doses of COTI-2 [1]. In vivo: The effects of COTI-2 on inhibiting the growth of HT-29 and SHP-77 xenografts in immunocompromised mice was assessed when intraperitoneally administered. It was found that COTI-2 at 10 mg/kg could significantly inhibit tumor growth in the HT-29 human colorectal tumor xenografts. In addition to reducing tumor volumes at specific times post-treatment, COTI-2 could also delay the time required for tumors to reach specified volumes [1].